Literature DB >> 10626853

Pulmonary hypertension associated with postoperative biliary atresia: report of two cases.

H Soh1, T Hasegawa, T Sasaki, T Azuma, A Okada, S Mushiake, S Kogaki, T Matsushita, T Harada.   

Abstract

The authors report on 2 patients with biliary atresia in whom pulmonary hypertension (PH) developed in the long-term follow-up after hepatoportoenterostomy. Both had portal hypertension and had undergone distal splenorenal shunt. Dyspnea developed around 14 to 15 years of age. Cardiac catheterization showed pulmonary artery pressure (PAP) of 99/37 (58) and 67/32 (48) mm Hg, respectively, which did not respond to vasodilators. One patient suffered from respiratory tract infection followed by right heart failure and subsequent death at 20 years of age. Postmortum histological findings exhibited severe thickening of the pulmonary artery wall. PH may grow insidiously even after successful hepatoportoenterostomy. Careful monitoring of PAP and hemodynamic response of PAP to vasodilators is essential for evaluating the reversibility of PH and making treatment decisions.

Entities:  

Mesh:

Year:  1999        PMID: 10626853     DOI: 10.1016/s0022-3468(99)90311-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Portopulmonary hypertension in pediatric patients.

Authors:  Adria A Condino; D Dunbar Ivy; Judith A O'Connor; Michael R Narkewicz; Sarah Mengshol; John R Whitworth; Lori Claussen; Aimee Doran; Ronald J Sokol
Journal:  J Pediatr       Date:  2005-07       Impact factor: 4.406

2.  Onset ages of hepatopulmonary syndrome and pulmonary hypertension in patients with biliary atresia.

Authors:  Takehisa Ueno; Ryuta Saka; Yuichi Takama; Hiroaki Yamanaka; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2017-09-04       Impact factor: 1.827

3.  Epidemiology of Biliary Atresia in Korea.

Authors:  Kyung Jae Lee; Ju Whi Kim; Jin Soo Moon; Jae Sung Ko
Journal:  J Korean Med Sci       Date:  2017-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.